UNSPSC 51111617: Gemcitabine

This classification denotes a ribonucleotide reductase inhibitor and pyrimidine antagonist with the molecular formula C9H11F2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B76N6SBZ8R, chemically known as 2-deoxy-.beta.-d-2,2-difluorocytidine but generally known as gemcitabine, which bears US NIH Compound Identifier 60750. European Medicines Agency schedules Gemcitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07892MIG.

UNSPSC 51111617 Gemcitabine is a Commodity code covering the pharmaceutical product gemcitabine, a chemotherapy agent used in cancer treatment protocols. State and local governments procure this drug primarily through health departments, correctional facilities, public hospitals, and healthcare systems to support oncology services and inmate medical care. Gemcitabine procurement typically occurs via standing contracts or blanket purchase orders with pharmaceutical distributors or manufacturers, often leveraging cooperative purchasing agreements or state pharmaceutical procurement frameworks to achieve volume discounts. The issuing bodies span state health agencies, county hospitals, municipal health departments, and specialized healthcare districts that operate treatment facilities.

The source provided contains no recent state and local contract opportunities tagged to this code, precluding characterization of current geographic activity or representative solicitations. Without posted RFP, RFQ, IFB, or ITB notices, pricing, volume signals, or issuing-body detail in the available data, pursuit decisions rest on direct outreach to state pharmaceutical procurement offices, correctional healthcare administrators, and public hospital group purchasing organizations rather than on posted market signals.